BELIEF phase II trial
Patients with EGFR Mut+ NSCLC and pre-existing T790M mutations who received first-line treatment with erlotinib plus bevacizumab, had significantly longer PFS than those patients who were T790M-negative.1
In patients who received erlotinib plus bevacizumab, PFS was significantly longer in those with pre-existing T790M mutations than those without.
AEs of any grade were common with combination treatment, however the majority of AEs were Grade ≤3
* 105 patients out of the 106 in the safety population had at least one adverse event. 29% of patients had a serious adverse event.
Please click here for further safety data
Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed